ADIL实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 May 2024 @ 04:00):

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders...

Stats
今日成交量	236 415
平均成交量	6.52M
市值	6.89M
EPS	$-1.154 ( 2024-04-04 )
下一个收益日期	( $-0.510 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.350
ATR14	$0.0150 (0.88%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-25	Gilliland Robertson H.	Buy	12 000	Stock Option (Right to Buy)
2024-03-25	Newman James W. Jr.	Buy	12 000	Stock Option (Right to Buy)
2024-03-25	Truluck Joseph	Buy	25 000	Stock Option (Right to Buy)
2024-03-25	Claiborne Cary J	Buy	60 000	Stock Option (Right to Buy)
2024-03-25	Anderson J. Kermit	Buy	12 000	Stock Option (Right to Buy)

INSIDER POWER
91.12
Last 98 transactions
Buy: 7 510 922 \| Sell: 1 943 977

音量相关性

長: -0.10 (neutral)

短: -0.74 (moderate negative)

Signal:(46.192) Neutral

Adial Pharmaceuticals Inc 相关性

10 最正相关
EXFY	0.967
ELEV	0.966
DRVN	0.965
GSIT	0.964
TSVT	0.963
CMBM	0.958
FGEN	0.956
IPGP	0.956
CMCT	0.952
NNOX	0.951

10 最负相关
NVAC	-0.958
PRDO	-0.955
MITA	-0.952
GHIXU	-0.943
WFRD	-0.939
BRIVU	-0.938
MSDA	-0.938
CCRC	-0.935
MMYT	-0.932
DSEY	-0.931

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Adial Pharmaceuticals Inc 相关性 - 货币/商品

0.17
( neutral )

-0.24
( neutral )

0.00
( neutral )

-0.50
( neutral )

0.07
( neutral )

Adial Pharmaceuticals Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-564.00 (0.00 %)
EPS:	$-5.44

FY	2023
营收:	$0
毛利润:	$-564.00 (0.00 %)
EPS:	$-5.44

FY	2022
营收:	$0
毛利润:	$-60 501.00 (0.00 %)
EPS:	$-317.81

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.971

Financial Reports:

No articles found.

Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.